60 Degrees Pharmaceuticals, Inc. (SXTP)
SXTPNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.5100
-0.0168 (-3.19%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $1.82m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.4800 to $8.62
- Average volume
- –
- Previous close
- $0.5268
Earnings
next estimate $-0.7300Next report
Mar 2026
-68.4%
Jun 2026
-21.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $529.0k | $316.0k | $162.0k | $208.0k |
| Gross profit | -$9,000 | $196.0k | $76.0k | $57.0k |
| Operating income | -$2.32m | -$1.92m | -$2.10m | -$2.27m |
| Net income | -$2.32m | -$1.44m | -$2.09m | -$2.27m |
Last four quarters: revenue $1.22m, margin -667.4%, free cash flow –
News
8 latest- Harrow (HROW) Q3 Earnings Lag EstimatesZacks · 6 days ago
- 60 Degrees Pharmaceuticals, Inc. Enters Inducement Agreements to Exercise Warrants for $526,042.80 Gross ProceedsFintel · Nov 6, 2026
- Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings EstimatesZacks · Nov 5, 2026
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals RTTNews · Oct 30, 2026
- 60 Degrees Pharma Expands Research Into Alpha-Gal Syndrome; Stock Up RTTNews · Oct 28, 2026
- 60 Degrees Pharmaceuticals, Inc. Reports Results from Expanded Access Babesiosis StudyFintel · Oct 27, 2026
- 60 Degrees Reports Negative Babesia PCR Results In Completed Expanded Access Patients; Stock Down RTTNews · Oct 27, 2026
- 60 Degrees Pharmaceuticals, Inc. Outlines Tafenoquine Clinical Program for Babesiosis and Potential sNDA in 2027Fintel · Oct 23, 2026
The company
60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company obtained U.S. Food and Drug Administration approval of its lead product, ARAKODA (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- 60degreespharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.